Real-world costs and outcomes in metastatic renal cell carcinoma patients treated by targeted therapies: a cohort study from the French health insurance database.

CONCLUSION: This descriptive study showed that the economic burden of mRCC is substantial with oral targeted therapies accounting for 53% of the PPPM. OS and PFS in real life are poorer than observed in clinical trials. PMID: 28748721 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research

Related Links:

CONCLUSION: This study showed that the use of a natural multicomponent mouthwash coupled with regular oral hygiene was able to reduce the severity and duration of everolimus-induced stomatitis in patients with RCC. TRIAL REGISTRATION NUMBER: ISRCTN14568888. PMID: 32364051 [PubMed - as supplied by publisher]
Source: Tumori - Category: Cancer & Oncology Tags: Tumori Source Type: research
Abstract Recombinant interleukin-2 (rIL-2) is indicated for metastatic renal cell carcinoma and melanoma. Over recent years low-dose rIL-2 has been studied for the treatment of autoimmune diseases and acute coronary syndrome because of its ability to expand and activate T regulatory (Treg) cells. However, several medical conditions potentially benefiting from rIL-2 administrations are characterized by an intrinsic prothrombotic risk, thus requiring concurrent anticoagulation. In our systematic review of the literature, we investigated the potential for drug interactions between oral anticoagulants and rIL-2 by ass...
Source: Hamostaseologie - Category: Hematology Authors: Tags: Hamostaseologie Source Type: research
chele Ghidini We performed a systematic review and meta-analysis to evaluate the role of gastric acid suppressant use on outcomes of tyrosine kinase inhibitors (TKIs) and oral chemotherapy. We identified all research evaluating the effect of GAS (gastric acid suppressants) use on patients receiving oral chemotherapy or TKIs for solid tumors. The pooled hazard ratios (HRs) and 95% confidence interval (95%CI) for overall survival (OS) and progression-free survival (PFS) were calculated with a fixed-effects or a random effects model. The study population included n = 16 retrospective studies and 372,418 patients. The seri...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
The localization of renal cell carcinoma metastases in the oral cavity has been reported, accounting for about the 15% of patients with metastasizing renal disease. In the present work, we report two cases of oral metastases of renal carcinoma, and provide a review of current literature on the occurrence of oral metastases of renal origin. The first patient (male, aged 62 years old) presented with a tumefaction of the body of the tongue. The second patient (male, aged 71 years old) showed a large mass localized in the buccal mucosa.
Source: Journal of Oral and Maxillofacial Surgery - Category: ENT & OMF Authors: Tags: Case Report Source Type: research
The localization of renal cell carcinoma (RCC) metastases in the oral cavity has been reported, accounting for about 15% of patients with metastasizing renal disease. In this work, we report 2 cases of oral metastases of renal carcinoma and provide a review of the current literature on the occurrence of oral metastases of renal origin. The first patient (a 62-year-old man) presented with a tumefaction of the body of the tongue.  The second patient (a 71-year-old man) showed a large mass localized in the buccal mucosa.
Source: Journal of Oral and Maxillofacial Surgery - Category: ENT & OMF Authors: Tags: Pathology Source Type: research
Conclusion: Renal tumors have more diverse microbiomes than normal adjacent tissue. Identification of resident oral microbiome profiles in clear-cell renal cancer with tumor thrombus provides a potential biomarker for thrombus response to PD-L1 inhibition. PMID: 32148479 [PubMed]
Source: Advances in Urology - Category: Urology & Nephrology Tags: Adv Urol Source Type: research
Abstract A 64-year-old man was treated with sunitinib as a first-line therapy for metastatic renal cell carcinoma. He was given oral sunitinib in cycles of 50 mg once daily for 2 weeks followed by a week off. During the 5th week of treatment right upper quadrant pain developed, but this resolved spontaneously during the 6th week (off treatment). However, on the 8th week of treatment, he was admitted to hospital because the acute right upper quadrant pain recurred with nausea, vomiting, and fever. Acute acalculous cholecystitis was then diagnosed by ultrasonography and CT. In addition, his laboratory findings indic...
Source: Korean J Gastroenter... - Category: Gastroenterology Authors: Tags: Korean J Gastroenterol Source Type: research
ConclusionsThis study demonstrates that splitting intake moments of pazopanib leads to a 79% increase in Cmin, with acceptable tolerability. Therefore, this new dosing schedule offers a cost-neutral opportunity to optimize treatment in patients with low exposure.Clinical Trial RegistrationNL6137 (http://www.trialregister.nl).
Source: Clinical Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research
The objective of this study is to assess the clinical benefit of SUN and PAZ in routine practice.MethodsWe reviewed the medical records of seventy-nine mRCC patients treated with SUN (50 mg/day on 4/2-schedule) or PAZ (800 mg/day continuously). Patients were assessed retrospectively at two Turkish hospitals between 2006 and 2016.ResultsFor the entire cohort median age of patients was 60 (28–87) years and 70% of them were male. The objective response rate (ORR) and disease control rate (DCR) in SUN/PAZ groups were 34/37% (p = 0.96) and 78/87% (p = 0.046), respectively. With a median follow up duration of 1...
Source: Actas Urologicas Espanolas - Category: Urology & Nephrology Source Type: research
Abstract CD28H and B7-H5 have been identified as receptor-ligand pairs in B7/CD28 family, and have costimulatory activity in immune cells. Here, we have systematically reviewed the research reports on the CD28H/B7-H5 pathway. It was found that CD28H is mainly expressed in T cells and natural killer (NK) cells with naive and poorly differentiated properties, and repeated antigen stimulation leads to permanent loss of CD28H. In tumors, CD28H is mainly expressed in tissue-resident memory (TRM ) lymphocyte T cells, which is associated with improved tumor prognosis. B7-H5 is a ligand for CD28H and is widely expressed i...
Source: Clinical and Developmental Immunology - Category: Allergy & Immunology Authors: Tags: Clin Exp Immunol Source Type: research
More News: Cancer & Oncology | Carcinoma | Clinical Trials | Databases & Libraries | France Health | Health Insurance | Insurance | Kidney Cancer | Oral Cancer | Renal Cell Carcinoma | Research | Study